Recombinant Opisthacanthus cayaporum Venom peptide Ocy2

What is Opisthacanthus cayaporum and where is this scorpion species found?

Opisthacanthus cayaporum is a scorpion species belonging to the Liochelidae family. The genus Opisthacanthus has a distribution spanning southern Africa, Central America, and South America, representing what researchers consider a true Gondwana heritage in terms of evolutionary biogeography . O. cayaporum specifically is endemic to open savannas in the eastern Amazonian region, particularly in the southern areas of the State of Pará and throughout the State of Tocantins in Brazil .

What is the molecular structure and basic characteristics of OcyKTx2?

OcyKTx2 is a 34 amino acid peptide isolated from Opisthacanthus cayaporum venom with a molecular mass of 3807 Da. The peptide contains four disulfide bridges that contribute to its structural stability and functional properties . Based on sequence comparison, chain length analysis, and disulfide bridge arrangement, OcyKTx2 has been classified into subfamily 6 of the α-KTx scorpion toxins and assigned the systematic name α-KTx6.17 . The peptide shares high sequence identity with other peptides in this subfamily, clustering closely in phylogenetic analyses.

How does OcyKTx2 compare to other peptides isolated from Opisthacanthus cayaporum venom?

Proteomic analysis of O. cayaporum venom has revealed a complex mixture containing at least 262 distinct molecular components with a trimodal molecular weight distribution . Within this venom, approximately 42% of components have molecular weights between 229.2-2985.3 Da, 37% fall within 3045.0-7258.6 Da (where OcyKTx2 is positioned), and about 12% are within 7458.4-9429.0 Da . Among the 17 peptides that have been sequenced from this venom, several demonstrate structural similarity to potassium channel blockers, including peptides that show 61-67% identity to α-KTx 6.10 toxin (OcKTx5) from Opistophthalmus carinatus and to Om-toxins from O. madagascariensis .

What are the recommended methods for recombinant expression of OcyKTx2?

For recombinant expression of OcyKTx2, researchers should consider the following methodology:

• Vector selection: Choose an expression vector with a strong promoter (such as T7) and appropriate fusion tags to facilitate purification.

• Expression system: E. coli BL21(DE3) is commonly used for scorpion peptide expression, though eukaryotic systems like Pichia pastoris may provide better disulfide bond formation.

• Optimization strategy: Express the peptide with a fusion partner (such as thioredoxin or SUMO) to enhance solubility and facilitate proper disulfide bond formation.

• Purification approach: Implement a two-step purification process:

  • Initial capture using affinity chromatography based on fusion tag

  • Further purification via reverse-phase HPLC with a C18 column using a linear gradient of 0-60% acetonitrile with 0.1% TFA

• Verification methods: Confirm peptide identity and purity through:

  • ESI-MS or MALDI-TOF-MS to verify molecular mass (expected 3807 Da)

  • Circular dichroism to assess secondary structure

  • Automated Edman degradation for N-terminal sequencing

What electrophysiological methods are suitable for assessing the ion channel blocking activity of OcyKTx2?

To evaluate the ion channel blocking activity of OcyKTx2, the following methodological approaches are recommended:

• Patch-clamp techniques: Whole-cell or excised patch configurations can be employed to directly measure K⁺ currents in the presence and absence of the peptide. These techniques allow for precise determination of blocking kinetics and dose-response relationships.

• Expression systems: Use either:

  • Xenopus oocytes injected with cRNA encoding Shaker B K⁺-channels or hKv1.3

  • Mammalian cell lines (HEK293, CHO) transfected with the appropriate ion channel genes

• Protocol design: Apply voltage protocols that activate the channels of interest, typically involving depolarizing steps from a hyperpolarized holding potential.

• Data analysis: Calculate the dissociation constant (Kd) using the Hill equation based on concentration-response curves. For OcyKTx2, previous studies determined a Kd of 82 nM for Shaker B K⁺-channels and approximately 18 nM for hKv1.3 channels .

• Control experiments: Include positive controls with known K⁺-channel blockers and ensure reversibility of the blocking effect by washout.

How can molecular dynamics simulations enhance our understanding of OcyKTx2's binding mechanism to K⁺ channels?

Molecular dynamics (MD) simulations offer valuable insights into the binding mechanisms of OcyKTx2 to K⁺ channels through the following methodological approaches:

• System preparation:

  • Generate a homology model of OcyKTx2 based on structurally similar α-KTx peptides if crystallographic data is unavailable

  • Create a simulation system with the peptide positioned near the extracellular entrance of an atomistic K⁺ channel model embedded in a lipid bilayer

• Simulation protocols:

  • Perform initial docking simulations to identify potential binding poses

  • Conduct extended (>100 ns) all-atom MD simulations to capture binding events and conformational changes

  • Implement enhanced sampling techniques such as steered MD or umbrella sampling to determine the energy landscape of binding

• Analysis approaches:

  • Calculate binding free energies using MM/PBSA or FEP methods

  • Identify key residue interactions through contact analysis and hydrogen bond monitoring

  • Compare simulation results with experimental mutagenesis data to validate binding predictions

This computational approach can reveal the structural determinants that contribute to OcyKTx2's higher affinity for hKv1.3 (Kd ~18 nM) compared to Shaker B channels (Kd 82 nM) , potentially guiding the rational design of more selective channel modulators.

How do post-translational modifications affect the activity and stability of recombinant OcyKTx2?

Post-translational modifications (PTMs) can significantly impact the activity and stability of recombinant OcyKTx2. The following methodological framework addresses this important research question:

• Identification of native PTMs:

  • Analyze native OcyKTx2 using high-resolution mass spectrometry to identify potential modifications

  • Employ bottom-up proteomics approaches with targeted enrichment for specific PTMs

  • Compare native and recombinant peptide profiles to identify modifications present only in the native form

• Assessment of disulfide bond patterns:

  • Determine the connectivity of the four disulfide bridges using partial reduction and alkylation followed by MS/MS analysis

  • Compare different expression systems for their ability to reproduce native disulfide bonding patterns

• Stability analysis:

  • Evaluate thermal stability using differential scanning calorimetry

  • Assess resistance to proteolytic degradation in different buffer conditions

  • Test long-term storage stability under various temperature and buffer conditions

• Functional comparison:

  • Perform comparative electrophysiological studies between native and recombinant peptides

  • Quantify differences in binding affinity and blocking kinetics

This methodological approach enables researchers to optimize expression systems and purification protocols to obtain recombinant OcyKTx2 with properties closely resembling the native peptide.

How does OcyKTx2 compare to other K⁺ channel blockers in terms of selectivity and potency?

OcyKTx2 demonstrates distinctive selectivity and potency profiles compared to other K⁺ channel blockers, as outlined in the following comparative analysis:

The comparative analysis reveals that while OcyKTx2 exhibits a moderately high affinity for hKv1.3 channels (Kd ~18 nM), it demonstrates less selectivity than some other scorpion-derived K⁺ channel blockers . This intermediate selectivity profile positions OcyKTx2 as a useful pharmacological tool for studies requiring partial but not complete selectivity between Kv1.3 and other K⁺ channel subtypes.

What are the structure-activity relationships that determine OcyKTx2's specificity for different K⁺ channel subtypes?

Understanding the structure-activity relationships (SARs) of OcyKTx2 requires a systematic approach combining experimental and computational methods:

• Key functional residues identification:

  • Perform alanine-scanning mutagenesis focusing on charged and aromatic residues

  • Measure changes in binding affinity and blocking kinetics for each mutant

  • Identify conserved functional motifs through sequence alignment with other α-KTx6 subfamily members

• Specificity determinants:

  • Generate chimeric peptides by exchanging segments between OcyKTx2 and related toxins with different selectivity profiles

  • Evaluate binding to various K⁺ channel subtypes including Kv1.1-1.6, Kv3.1, and BK channels

  • Identify regions responsible for subtype specificity

• Binding mode characterization:

  • Implement site-directed mutagenesis of the channel pore region to disrupt specific toxin-channel interactions

  • Use double-mutant cycle analysis to quantify the energetic contribution of individual interaction pairs

The lysine residue at position 27 (based on similar α-KTx peptides) likely serves as the crucial "functional dyad" element that physically occludes the channel pore, while surrounding residues determine subtype specificity through interactions with the channel vestibule .

What is the potential of OcyKTx2 as a lead compound for developing immunomodulatory drugs targeting Kv1.3 channels?

OcyKTx2 shows promising potential as a lead compound for developing immunomodulatory drugs targeting Kv1.3 channels through the following evidence-based rationale:

• Target validation:

  • Kv1.3 channels are highly expressed in effector memory T cells implicated in autoimmune disorders

  • Selective Kv1.3 blockers have demonstrated efficacy in preclinical models of multiple sclerosis, rheumatoid arthritis, and psoriasis

• Advantages of OcyKTx2 as a scaffold:

  • Nanomolar affinity for hKv1.3 (Kd ~18 nM)

  • Compact size (34 amino acids) amenable to synthetic modification

  • Well-defined structural scaffold stabilized by four disulfide bridges

• Optimization strategy:

  • Enhance selectivity through targeted mutations of residues interacting with the channel vestibule

  • Improve pharmacokinetic properties by strategic PEGylation or conjugation to half-life extension domains

  • Develop non-immunogenic variants through elimination of T-cell epitopes

• Delivery approaches:

  • Explore alternative administration routes (subcutaneous, transdermal) to bypass gastrointestinal degradation

  • Develop nanoparticle-based delivery systems to enhance tissue-specific targeting

This translational research direction leverages OcyKTx2's moderately selective Kv1.3 blocking activity while addressing the pharmacokinetic and immunogenicity challenges typical of peptide therapeutics.

How can researchers address the challenges of peptide stability and delivery when developing OcyKTx2-based therapeutics?

Addressing peptide stability and delivery challenges for OcyKTx2-based therapeutics requires a multifaceted approach:

• Chemical modifications to enhance stability:

  • N-terminal acetylation and C-terminal amidation to protect against exopeptidases

  • Introduction of non-natural amino acids (e.g., D-amino acids) at susceptible positions

  • Cyclization strategies to enhance resistance to proteolytic degradation

• Formulation strategies:

  • Development of controlled-release systems using biodegradable polymers

  • Encapsulation in liposomes or nanoparticles to protect against proteolytic degradation

  • Use of permeation enhancers for potential mucosal delivery

• Alternative delivery approaches:

  • Evaluation of non-invasive delivery routes (intranasal, buccal, inhalation)

  • Development of cell-penetrating peptide conjugates for enhanced cell permeability

  • Exploration of targeted delivery using antibody-toxin conjugates

• Production considerations:

  • Optimization of recombinant expression systems for disulfide-rich peptides

  • Scale-up strategies for GMP-compliant manufacturing

  • Implementation of analytical methods for batch-to-batch consistency assessment

These approaches can systematically address the typical limitations of peptide therapeutics while preserving the essential ion channel blocking activity of OcyKTx2.

What are common pitfalls in recombinant production of OcyKTx2 and how can they be addressed?

Researchers frequently encounter several challenges when producing recombinant OcyKTx2. The following methodological guidance addresses these issues:

• Challenge: Incorrect disulfide bond formation

  • Solution: Implement oxidative refolding protocols using optimized glutathione redox systems (GSH:GSSG ratios of 1:1 to 10:1)

  • Alternative approach: Co-express with disulfide isomerases or use eukaryotic expression systems with enhanced disulfide formation capacity

• Challenge: Low solubility and inclusion body formation

  • Solution: Express as fusion proteins with solubility-enhancing partners such as thioredoxin, MBP, or SUMO

  • Alternative approach: Optimize induction conditions (lower temperature, reduced IPTG concentration)

• Challenge: Proteolytic degradation during expression

  • Solution: Use protease-deficient host strains and include protease inhibitors during purification

  • Alternative approach: Design constructs with stabilizing terminal extensions that can be removed post-purification

• Challenge: Low yield after purification

  • Solution: Implement stepwise optimization of each purification stage with recovery assessment

  • Alternative approach: Explore direct expression into the culture medium using appropriate signal peptides

• Challenge: Loss of activity after purification

  • Solution: Conduct activity assays throughout purification to identify problematic steps

  • Alternative approach: Include stabilizing agents (glycerol, specific ions) in storage buffers

This troubleshooting guide facilitates the successful production of functional recombinant OcyKTx2, minimizing common experimental failures.

How should researchers design experiments to investigate potential off-target effects of OcyKTx2?

Designing experiments to investigate off-target effects of OcyKTx2 requires a systematic, multi-platform approach:

• In vitro screening against ion channel panels:

  • Test against a comprehensive panel of voltage-gated and ligand-gated ion channels

  • Use automated patch-clamp platforms for higher throughput

  • Determine IC50 values for each channel type to create a selectivity profile

• Receptor binding assays:

  • Screen against G-protein coupled receptors and other membrane receptors using radioligand displacement assays

  • Identify potential interactions with unintended molecular targets

• Cell-based functional assays:

  • Assess effects on cell viability, proliferation, and morphology in various cell types

  • Evaluate impact on calcium signaling using fluorescent indicators

  • Test for immunogenicity using human peripheral blood mononuclear cells

• Toxicity assessment:

  • Perform hemolysis assays to evaluate membrane-disruptive properties

  • Assess mitochondrial function using respirometry and membrane potential indicators

  • Evaluate potential neuronal off-target effects using primary neuronal cultures

• Data integration:

  • Develop an integrated scoring system to rank observed off-target effects by severity and dose relationship

  • Compare with known toxicity profiles of related peptides to identify class-specific versus compound-specific effects

This comprehensive experimental design enables researchers to develop a complete safety profile for OcyKTx2, facilitating informed decisions about its potential therapeutic applications.

What are promising research directions for developing OcyKTx2 analogs with enhanced selectivity for specific K⁺ channel subtypes?

Several promising research directions for developing OcyKTx2 analogs with enhanced selectivity include:

• Rational design approach:

  • Perform comprehensive alanine scanning to create a functional map of the peptide

  • Introduce amino acid substitutions at positions that interact with divergent regions of different K⁺ channel subtypes

  • Apply computational modeling to predict changes in binding energy and selectivity

• Directed evolution strategies:

  • Develop yeast or phage display libraries of OcyKTx2 variants

  • Implement selection schemes that favor binding to desired channel subtypes

  • Combine multiple beneficial mutations to obtain synergistic improvements in selectivity

• Chimeric toxin engineering:

  • Create chimeric peptides combining segments of OcyKTx2 with highly selective toxins like margatoxin

  • Systematically evaluate the contribution of different segments to subtype selectivity

  • Optimize linker regions between functional domains

• Chemical modification approach:

  • Introduce site-specific chemical modifications such as glycosylation or PEGylation

  • Evaluate how modifications at different positions affect channel subtype selectivity

  • Develop dual-warhead inhibitors by conjugating OcyKTx2 with other pharmacophores

These research directions hold promise for developing next-generation K⁺ channel modulators with tailored selectivity profiles for specific therapeutic applications or as pharmacological tools.

How might high-resolution structural studies of OcyKTx2 bound to its target channels advance our understanding of ion channel pharmacology?

High-resolution structural studies of OcyKTx2-channel complexes would significantly advance ion channel pharmacology through several key contributions:

• Structural determination methods:

  • Cryo-electron microscopy of OcyKTx2 bound to purified K⁺ channels reconstituted in nanodiscs

  • X-ray crystallography of engineered channel-toxin complexes stabilized through covalent linkages

  • NMR studies of labeled toxin interacting with channel vestibule peptides

• Mechanistic insights to be gained:

  • Atomic-level understanding of the binding interface and key interaction residues

  • Conformational changes in both toxin and channel upon binding

  • Structural basis for differences in affinity between channel subtypes

• Translation to drug design:

  • Identification of previously unknown binding pockets or interaction sites

  • Structure-guided optimization of selectivity and potency

  • Development of non-peptidic mimetics based on critical pharmacophores

• Technical innovations required:

  • Development of stabilized channel constructs amenable to structural studies

  • Implementation of advanced computational methods to model flexibility in the binding interface

  • Integration of structural data with functional electrophysiology

These structural studies would bridge the gap between sequence-based analyses and functional studies, providing a rational foundation for the development of subtype-selective K⁺ channel modulators with therapeutic potential.